HTx Outcomes Research Articles

Outcome in Children Bridged and Nonbridged to Cardiac Transplantation

BackgroundHeart transplantation (HTx) in children with end-stage heart disease has become an accepted treatment option. ObjectiveTo evaluate our results of pediatric cardiac transplantation with vs without bridge methods. Patients and MethodsThe study included 31 patients (34 transplantations) younger than 18 years who underwent orthotopic HTx between March 1995 and December 2008. Ten patients were girls, and 21 were boys. Preoperative diagnoses included cardiomyopathy (n = 20), congenital heart disease (n = 7), hypertrophic cardiomyopathy (n = 2), restrictive cardiomyopathy (n = 1), and ischemic cardiomyopathy (n = 1). Mean (SD) ischemia time was 185 (72) minutes. Thirty-day mortality was 6%, and was due to primary graft failure (n = 2). Overall follow-up was 4.36 (3.93) years. Eleven patients underwent bridge techniques before HTx, and 11 patients required perioperative extracorporeal membrane oxygenation or ventricular assist device support. ResultsIn the group that received extracorporeal membrane oxygenation, 8 patients (73%) were successfully weaned and discharged with excellent functional class. There were no differences in operative mortality, functional class, survival, rejection, and infection rates between the bridged and nonbridged groups. Overall actuarial 1- and 5-year survival rates were 93% and 83%, respectively. All survivors had good functional class. ConclusionOur findings demonstrate satisfactory medium-term outcome of HTx in selected pediatric patients with end-stage heart disease. Using bridge methods in children at high risk can increase the opportunity to receive a donor heart. These bridge methods achieve similar postoperative outcomes.

Clinical Course and Outcome of Heart Transplant Recipients Single Center Experience at the National Cardiovascular Center in Japan

The number of heart transplant (HTx) surgeries in Japan is expected to increase under the Revised Organ Transplant Law. To date, among 69 HTx surgeries performed in Japan, 27 operations (39.1%) were performed at our institution, the National Cardiovascular Center (NCVC), located in Osaka. We have reviewed the outcomes of HTx conducted at NCVC during a 10 year period (May 1999 to January 2009). Among 27 heart transplant recipients at NCVC, the clinical charts of 26 recipients whose post-HTx period exceeded 1 year were retrospectively reviewed and compared to data from the International Society for Heart and Lung Transplantation (ISHLT) Registry. The survival rate of our recipients was 96.2% at 10.8 years, which was excellent even compared to the ISHLT Registry. The immunosuppressive regimen at NCVC was equivalent to that of the ISHLT Registry, except for more frequent use of Muromonab-CD3 (26.9% versus 3.3%, P < 0.0001) and an initial CSA-based regimen (65.3% versus 34.4%, P < 0.001). The drug we use for induction therapy has been recently changed from Muromonab-CD3 to Basiliximab. The incidences of post-HTx hypertension, diabetes, hyperlipidemia, and renal insufficiency were significantly less in patients at NCVC compared to those in the ISHLT Registry, however, the incidence of transplant coronary artery disease (TxCAD) was almost identical. Clinical review of post-HTx outcome at NCVC can provide useful information for Japanese transplant cardiologists who will engage in HTx management.

Outcomes of Pediatric Patients Bridged to Heart Transplantation from Extracorporeal Membrane Oxygenation Support

Extracorporeal membrane oxygenation (ECMO) is used as a salvage therapy in children with irreversible myocardial failure who may be candidates for heart transplantation (HTx) (at the Hospital for Sick Children). We retrospectively assessed outcomes of children wait-listed for HTx from ECMO, and risk factors for patients (pts) bridged to HTx from January 1990 through December 2005. Of 205 patients supported with cardiac ECMO, 46 were wait-listed for HTx. Sixteen patients died before HTx: eight died while wait-listed on ECMO; eight were delisted (clinical deterioration; all died); five were delisted (improved), and 25 (54%) underwent HTx from ECMO. Of 25 patients who underwent HTx (median age 7.0 years [10 days to 17 years]), 13 had myocarditis or cardiomyopathy, and 12 had congenital heart disease. Median ECMO duration was 6.7 days (3-18 days). Median follow-up was 4.3 years (0.2-10.6 years). Four patients died <1 week post-HTx, and 21 survived until hospital discharge (84%). Post-transplant survival was 67% and 52% at 1 and 5 years, respectively. Risk factors for early death were older age, higher body surface area, higher creatinine before and during ECMO, fungal infections, and exposure to blood products. In summary, few risk factors preclude HTx candidacy from ECMO. The impact of newer assist technology on ECMO, wait-list mortality, and HTx outcomes remains to be elucidated.

Principles of hepatocyte repopulation.

Hepatocyte transplantation (HTx) is technically feasible and can be clinically beneficial. Current research focuses on optimizing parameters which relate to the outcome of HTx, including site of transplantation, cell number and, most notably, the preferred cell type to be transplanted (differentiated adult vs. fetal hepatocytes vs. putative progenitor or precursor cells). However, the single major impediment towards the clinical effectiveness of HTx is the limited expansion of donor cells in the recipient liver. To this end, a relative growth advantage must be present or is to be imposed on transplanted hepatocytes versus resident cells. Possible strategies are presented and discussed.

Long ischaemic time allografts (>6hr) further expand the transplant donor pool

Background: With HTx numbers falling internationally reflecting a diminishing donor pool, and the acceptance that long allograft ischaemic time is a predictor of 1 and 5 year mortality (ISHLTx 2000 data), we reviewed the outcomes of HTx using 44 long ischaemic time (>6 hrs) allografts (LIA) compared to 326 “normal” (< 6 hrs) allografts (NIA) performed since March 1989. Our rationale for the utility of LIA’s was an effort to minimise donor organ wastage, accepting that VAD support and heterotopic heart transplantation (HHTx) were necessary management options.